Emergent BioSolutions (EBS) Set to Announce Quarterly Earnings on Wednesday

Emergent BioSolutions (NYSE:EBS - Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Emergent BioSolutions to post earnings of $0.49 per share for the quarter. Emergent BioSolutions has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that are interested in participating in the company's earnings conference call can do so using this link.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. The company had revenue of $254.70 million during the quarter, compared to analyst estimates of $199.47 million. During the same quarter last year, the company posted ($1.06) EPS. On average, analysts expect Emergent BioSolutions to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Emergent BioSolutions Stock Performance

EBS traded up $0.03 on Wednesday, reaching $9.36. The company had a trading volume of 130,025 shares, compared to its average volume of 3,454,041. The company's fifty day moving average is $8.37 and its 200 day moving average is $7.39. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The stock has a market cap of $490.48 million, a P/E ratio of -0.85 and a beta of 1.59. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Rodman & Renshaw restated a "buy" rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark reiterated a "buy" rating and set a $8.00 price target on shares of Emergent BioSolutions in a research report on Friday, August 16th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.